Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
Cabaletta Bio, Inc. (CABA)
Company Research
Source: GlobeNewswire
– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period – – Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional naïve B cell repopulation as early as eight weeks in the first two patients – – 40 U.S. clinical sites actively recruiting across the RESET™ clinical development program, with 16 patients enrolled and 10 patients dosed with CABA-201 as of November 12, 2024 – – Company to host live investor conference call and webcast
Show less
Read more
Impact Snapshot
Event Time:
CABA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CABA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CABA alerts
High impacting Cabaletta Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CABA
News
- Cabaletta Bio, Inc. (NASDAQ: CABA) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $6.00 price target on the stock, down previously from $15.00.MarketBeat
- Cabaletta Bio, Inc. (NASDAQ: CABA) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $6.00 price target on the stock, down previously from $12.00.MarketBeat
- Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio, Inc. (NASDAQ: CABA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.MarketBeat
- Cabaletta Bio to Participate in Upcoming Investor Conferences in December [Yahoo! Finance]Yahoo! Finance
CABA
Earnings
- 11/14/24 - Miss
CABA
Sec Filings
- 12/6/24 - Form SC
- 12/5/24 - Form SC
- 12/5/24 - Form SC
- CABA's page on the SEC website